Measurement of radioactivity in breast milk following 99mTc-Leukoscan injection.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78078
Title:
Measurement of radioactivity in breast milk following 99mTc-Leukoscan injection.
Authors:
Prince, Jennie R; Rose, Marge R
Abstract:
BACKGROUND: There are no published data on the excretion of radioactivity into breast milk following the administration of 99mTc sulesomab (Leukoscan). We report the results of measurements made on breast milk samples from one patient following Leukoscan injection. RESULTS: The activity concentration in the samples decayed mono-exponentially with an effective half-life of 3.1 h. Based on data from this patient, the interruption period required to reduce the radiation dose to the infant to less than 1 mSv following an administration of 750 MBq 99mTc-leukoscan would be 10 h. CONCLUSION: This information is useful as a guide to the likely period of interruption required when counselling a breastfeeding patient prior to a Leukoscan study.
Affiliation:
North Western Medical Physics, Christie Hospital NHS Trust, Withington, Manchester M20 4BX, UK. jennie.prince@physics.cr.man.ac.uk
Citation:
Measurement of radioactivity in breast milk following 99mTc-Leukoscan injection. 2004, 25 (9):963-6 Nucl Med Commun
Journal:
Nuclear Medicine Communications
Issue Date:
Sep-2004
URI:
http://hdl.handle.net/10541/78078
PubMed ID:
15319603
Type:
Article
Language:
en
ISSN:
0143-3636
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorPrince, Jennie R-
dc.contributor.authorRose, Marge R-
dc.date.accessioned2009-08-20T15:54:20Z-
dc.date.available2009-08-20T15:54:20Z-
dc.date.issued2004-09-
dc.identifier.citationMeasurement of radioactivity in breast milk following 99mTc-Leukoscan injection. 2004, 25 (9):963-6 Nucl Med Communen
dc.identifier.issn0143-3636-
dc.identifier.pmid15319603-
dc.identifier.urihttp://hdl.handle.net/10541/78078-
dc.description.abstractBACKGROUND: There are no published data on the excretion of radioactivity into breast milk following the administration of 99mTc sulesomab (Leukoscan). We report the results of measurements made on breast milk samples from one patient following Leukoscan injection. RESULTS: The activity concentration in the samples decayed mono-exponentially with an effective half-life of 3.1 h. Based on data from this patient, the interruption period required to reduce the radiation dose to the infant to less than 1 mSv following an administration of 750 MBq 99mTc-leukoscan would be 10 h. CONCLUSION: This information is useful as a guide to the likely period of interruption required when counselling a breastfeeding patient prior to a Leukoscan study.en
dc.language.isoenen
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshBreast-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInjections-
dc.subject.meshMetabolic Clearance Rate-
dc.subject.meshMilk, Human-
dc.subject.meshRadiopharmaceuticals-
dc.titleMeasurement of radioactivity in breast milk following 99mTc-Leukoscan injection.en
dc.typeArticleen
dc.contributor.departmentNorth Western Medical Physics, Christie Hospital NHS Trust, Withington, Manchester M20 4BX, UK. jennie.prince@physics.cr.man.ac.uken
dc.identifier.journalNuclear Medicine Communicationsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.